These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 17003081

  • 1. Renin-angiotensin system mediators and Raynaud's phenomenon.
    Wood HM, Ernst ME.
    Ann Pharmacother; 2006 Nov; 40(11):1998-2002. PubMed ID: 17003081
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE, Shea B, Welch V, Fenlon D, Pope JE.
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 6. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.
    Jennings DL, Taber DJ.
    Ann Pharmacother; 2008 Jan; 42(1):116-20. PubMed ID: 18094340
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system.
    Brunner HR, Nussberger J, Waeber B.
    J Hypertens Suppl; 1993 Apr; 11(3):S53-8. PubMed ID: 8315521
    [Abstract] [Full Text] [Related]

  • 8. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Wade VL, Gleason BL.
    Ann Pharmacother; 2004 Apr; 38(7-8):1278-82. PubMed ID: 15187210
    [Abstract] [Full Text] [Related]

  • 9. The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus.
    Coyle JD, Gardner SF, White CM.
    Ann Pharmacother; 2004 Oct; 38(10):1731-8. PubMed ID: 15353571
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
    Gales BJ, Bailey EK, Reed AN, Gales MA.
    Ann Pharmacother; 2010 Feb; 44(2):360-6. PubMed ID: 20086184
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K, Miller NH.
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ.
    Prev Cardiol; 2008 Jan; 11(4):215-22. PubMed ID: 19476574
    [Abstract] [Full Text] [Related]

  • 16. ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X.
    Feldman R.
    Can J Cardiol; 2000 Aug; 16 Suppl E():41E-44E. PubMed ID: 10906626
    [Abstract] [Full Text] [Related]

  • 17. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS, Morillo CA, Connolly SJ.
    Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
    [Abstract] [Full Text] [Related]

  • 18. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
    Richter B, Derntl M, Marx M, Lercher P, Gössinger HD.
    Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
    [Abstract] [Full Text] [Related]

  • 19. Phosphodiesterase inhibitors in Raynaud's phenomenon.
    Levien TL.
    Ann Pharmacother; 2006 Jan; 40(7-8):1388-93. PubMed ID: 16835313
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.